Novartis Net Worth is$150.4 B
VN:F [1.9.22_1171]
deserves the money?
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Would you date ?
Rating: 0.0/5 (0 votes cast)
Company Name: Novartis International AG

Company Logo: Image:Novartis.svg

Company Type: Public company Aktiengesellschaft

Traded As: NOVN, NVS

Foundation: 1996 (from merger)

Location: Basel, Switzerland

Key People: Daniel Vasella (Chairman), Joseph Jimenez (chief executive officer)

Industry: Pharmaceutical industry

Products: Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, Medical diagnosis, contact lenses, Veterinary medicine (#Products)

Revenue: url

Operating Income: net income

Assets: equity

Num Employees: homepage

Subsid: Ciba Vision, Sandoz, Alcon, Chiron Corporation

List: yes

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010.
Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include cyclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to NestlA(C) on 1 September 2007.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Novartis was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies with long histories. Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy Ltd (founded in Basel in 1758) and CIBA (founded in Basel in 1859). Combining the histories of the merger partners, the company's effective history spans 250 years.
In 1859, Alexander Clavel (1805a??1873) took up the production of fuchsine in his factory for silk-dyeing works in Basel. In 1864, a new site for the production of synthetic dyes was constructed, and in 1873, Clavel sold his dye factory to the new company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company with the name "Gesellschaft fA 1/4 r Chemische Industrie Basel" (Company for Chemical Industry Basel). The acronym, CIBA, was adopted as the company's name in 1945.
Johann Rudolf Geigy-Gemuseus (1733a??1793) began trading in 1758 in "materials, chemicals, dyes and drugs of all kinds" in Basel, Switzerland. Johann

Novartis Latest News

New Blood: Former Novartis Exec Transitions to Rubius Therapeutics

David Epstein has spent nearly 30 years in the pharmaceutical industry — first as the head of Novartis Oncology, which he helped grow into the world’s second largest cancer company, and then as the head of Novartis Pharmaceuticals. Along the way, he ...
Posted: August 17, 2017, 1:00 am

New Novartis drug to be used in treating drug-resistant malaria

Novartis has launched clinical trials of the first new antimalarial medicine in nine countries across Africa and Asia targeting drug-resistant malaria. Initial tests suggest KAF156 has potential to clear malaria infection, including resistant strains, as ...
Posted: August 21, 2017, 3:49 am

Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing

David Mitchell had just finished a five-hour infusion of drugs to keep his multiple myeloma under control when he decided to dash off a letter to Joe Jimenez, CEO of Novartis, requesting a meeting about how the company plans to price tisagenlecleucel ...
Posted: August 21, 2017, 11:58 am

New Novartis drug takes aim at tough-to-treat malaria

LONDON (Reuters) - Novartis is taking aim at drug-resistant malaria – a growing global problem – by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia. The Swiss drugmaker, which is ...
Posted: August 21, 2017, 1:01 am

Novartis AG And Launch Patient Trial In Africa For KAF156, A Novel Compound Against Multidrug-Resistant Malaria

Basel, August 21, 2017-Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the ...
Posted: August 21, 2017, 11:13 am
Related Topics:
How Much Is Novartis Earnings, How Much Is Novartis Income, How Much Is Novartis Net Worth, How Much Is Novartis Salary, How Much Is Novartis Worth, Novartis, Novartis Ag, Novartis Age, Novartis Animal Health, Novartis Animal Health Rebates, Novartis Atlanta, Novartis Bio, Novartis Careers, Novartis Consumer Health, Novartis Country, Novartis Date Of Birth, Novartis Duluth Ga, Novartis Earnings, Novartis Ethnicity, Novartis Gossips, Novartis Height, Novartis History, Novartis Home Town, Novartis Images, Novartis Income, Novartis India, Novartis Institutes For Biomedical Research, Novartis Job, Novartis Jobs, Novartis Miami, Novartis Nationality, Novartis Net Worth, Novartis Networth, Novartis News, Novartis Oncology, Novartis Partner, Novartis Pharmaceuticals, Novartis Pharmaceuticals Corp, Novartis Pharmaceuticals Corporation, Novartis Pipeline, Novartis Place Of Birth, Novartis Products, Novartis Recall, Novartis Rumors, Novartis Salary, Novartis Secrets, Novartis Sentinel, Novartis Vaccines, Novartis Venture Fund, Novartis Videos, Novartis Weight, Novartisrebates, Who Is Novartis,,